Do Not Prescribe (DNP), Red
Decision Date:
January 2023


RED: Monotherapy for the treatment of adults with relapsed and refractory multiple myeloma, who have received ≥3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy

DNP: NICE TA869 - Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (Terminated appraisal) (Decision date - March 2023)

Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app